Southeast Regional Radiation Medical Center Registers Patent for Substance Enhancing Cancer Treatment Effectiveness

Patent Composition Containing Anmindenol A Derivative Promotes Cancer Cell Apoptosis and Inhibits Proliferation

The Tumor Bio Research Team at the Southeast Regional Radiation Medical Center (Medical Director Changhoon Lee) recently completed the patent registration for a "composition for enhancing radiosensitivity and for preventing or treating tumors containing anmindenol derivatives as active ingredients."

The Tumor Bio Research Team has been conducting research since 2021 to discover new anticancer drugs that enhance cancer cell response to radiation therapy and improve the efficiency of radiation treatment. For this research, they received the anticancer candidate compound anmindenol A analog synthesized by Professor Hwayoung Yoon's research team in the Department of Pharmacy at Pusan National University.

The research team confirmed that in a mouse breast cancer cell line, the combination of radiation and the anmindenol A analog AM-18002 reduced cell viability, tumor formation rate, and cell motility and invasiveness compared to radiation treatment alone.

Additionally, treatment with AM-18002 decreased myeloid-derived suppressor cells (MDSCs), which are increased by cancer cells, and was found to be more effective in inducing DNA damage.

The related research paper (corresponding author Yujin Choi, first author Dayoung Eom) titled "AM-18002, a derivative of natural anmindenol A, enhances radiosensitivity in mouse breast cancer cells" was published in the April 2024 issue of the international scientific journal PLOS ONE.

This research was conducted as part of the government-supported project at the Southeast Regional Radiation Medical Center titled "Establishment of Tumor Models and Study of Therapeutic Mechanisms for Overcoming Intractable Cancers" (Principal Investigator Siho Choi). Dayoung Eom, the first author of the paper, received the Excellent Poster Presentation Award and Travel Award at the 2022 Fall International Conference of the Korean Pharmaceutical Society, and in October 2023, she also won the Oral Presentation Award at the Fall International Conference of the Korean Pharmaceutical Society, achieving a triple crown and gaining significant attention in the academic community.

Researcher Da-Young Eom, Tumor Bio Research Team, Southeast Regional Radiation Oncology Hospital.

This content was produced with the assistance of AI translation services.